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Introduction
Systemic juvenile idiopathic arthritis (SJIA) is character-
ized by fevers, rash, and chronic arthritis, and interleukin
-1 (IL-1) and IL-6 inhibitors seems to be effective treat-
ments. Pulmonary arterial hypertension (PAH) and
macrophage activation syndrome (MAS), which is a
unremitting fever, coagulopathy, pancytopenia, and mul-
tiple organ dysfunction. These complications can be fatal
and may be the result of severe uncontrolled systemic
disease activity or influenced by medication exposure.
Objectives
Describe a 7 year old girl with systemic JIA complicated
with macrophage activation syndrome and pulmonary
arterial hypertension refractory to numerous treatments,
with good response to canakinumab, IL-1 inhibitor.
Methods
Female patient was diagnosed with systemic JIA at seven
year old. At eight years, was hospitalized with desease
reactivation in use of cyclosporin and oral prednisone.
An echocardiogram showed mild pericardial effusion and
moderate PAH (69mmHg), ferritin:5.865mg/dL, triglycer-
ides 428mg/dL, fever, splenomegaly and macrophage
activity in bone marrow fulfilled the macrophage activa-
tion syndrome (MAS) criteria. Methylprednisolone pulse
was started and echocardiographic control showed mild
improvement. Anti IL-6 therapy (tocilizumab - 8mg/kg)
was started every two weeks, total of 2 doses. Initially,
there was clinical improvement and decrease in pulmon-
ary artery pressure (PAP) to 38 mmHg. However, one
week later, a new echocardiogram showed mild PH
(44mmHg), new pericardial effusion and acute relapse of
disease symptoms (fever, rash, adenophathy) and new
MAS (ferritin 30.000mg/dl, triglycerides 500mg/dL). The
patient underwent a new pulse methylprednisolone and
oral prednisolone resulting in clinical improvement and
after the second dose of tocilizumab, high transaminases
levels were observed indicating anti-IL-6 suspension.
After one month, she had a new clinical decompensation
with signs of heart failure requiring intensive care. Echo-
cardiogram showed PAP of 95mmHg. A new methyl-
prednisolone pulse therapy was prescribed. After clinical
stabilization, received the first dose of IL-1 inhibitor. Sec-
ond dose of Canakimumabe was performed 4 weeks
later, and, at this moment PAP was 48mmHg in absence
of fever, rash, arthritis and reduced hepatosplenomegaly.
Results
In the present case, the patient developed MAS and pul-
monary hypertension and had important clinical
improvement with anti IL-1 theraphy. MAS is thought to
be an acquired form of hemophagocytic lymphohistiocy-
tosis, the real incidence in systemic JIA is not known, but
studies show that there are histological changes in the
bone marrow, even without clinical symptoms in many
patients. HP is a rare condition where immunosuppres-
sants and biological agents may be involved. Diagnose is
difficult, but we should have protocols to search it.
Conclusion
Systemic JIA can be complicated, among others, by
MAS and pulmonary arterial hypertension (PAH).
Further prospective studies are needed to determine the
real factors associated with the development of pulmon-
ary complications.
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